Joshua Brody, MD

Articles

Dr. Brody on the Role of Immunotherapy in Hodgkin Lymphoma

December 14th 2020

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Dr. Brody on the Expanding Role of Venetoclax in MCL

December 3rd 2020

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

November 25th 2020

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Dr. Brody on the Potential Role for Bispecific Antibodies in MCL

November 18th 2020

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Dr. Brody on the Challenges of Antigen Escape in MCL

November 12th 2020

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Dr. Brody on Modulating Fas Signaling to Prevent Relapse in Hematologic Malignancies

June 12th 2020

Joshua Brody, MD, discusses Fas and its impact on bystander killing in patients with non-Hodgkin lymphoma.

Dr. Brody on Addressing Acquired Resistance to Immunotherapy in Non-Hodgkin Lymphoma

May 28th 2020

Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.

Dr. Brody on the Role of Immunotherapy in Indolent Lymphomas

April 22nd 2020

Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.

Dr. Brody on Tolerability of In-Situ Vaccines in Indolent Non-Hodgkin Lymphoma

April 16th 2020

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Dr. Brody on In Situ Vaccinations for Hematologic Cancers

February 28th 2020

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.

Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL

November 24th 2014

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

Novel Vaccine Induces Durable Remissions in Patients With Advanced Lymphoma

November 25th 2013

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.